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Abstract
 
Aims
 
While the downstream effects of increased reactive oxygen species (ROS) in
the pathogenesis of diabetes were well studied, only a few studies have explored
the cellular sources of ROS. We examined whether protection against oxidative
stress is altered in patients with diabetes and microangiopathy by examining
changes in NADPH oxidase (p22
 
phox
 
) and hemoxygenase-1 (HO-1) levels.
 
Methods
 
NADPH oxidase (p22
 
phox
 
) and HO-1 gene expression were probed
by RT-PCR using leucocytes from patients with Type 2 diabetes without (
 
n
 
 =
19) and with microangiopathy (
 
n
 
 = 20) and non-diabetic subjects (
 
n
 
 = 17). Levels
of lipid peroxidation as measured by thiobarbituric reactive substances (TBARS)
and protein carbonyl content (PCO) were determined by fluorimetric and
spectrophotometric methods, respectively.
 
Results
 
p22
 
phox
 
 gene expression (mean 
 
±
 
 
 
SE
 
) was significantly (
 
P <
 
 0.05) higher
in diabetic patients with (0.99 
 
±
 
 0.04) and without microangiopathy (0.86 
 
±
 
0.05) compared with control subjects (0.66 
 
±
 
 0.05). Consistent with the mRNA
data, the p22
 
phox
 
 protein expression and NADPH oxidase activity was also in-
creased in cells from diabetic patients compared with control subjects. However,
HO-1 gene expression was significantly (
 
P <
 
 0.05) lower in patients with (0.73 
 
±
 
0.03) and without microangiopathy (0.85 
 
±
 
 0.02) compared with control subjects
(1.06 
 
±
 
 0.03). The mean (
 
±
 
 
 
SE
 
) levels of TBARS were significantly (
 
P <
 
 0.05) higher
in diabetic patients with (14.36 
 
±
 
 1.3 n
 
M
 
/ml) and without microangiopathy
(12.20 
 
±
 
 1.3 n
 
M
 
/ml) compared with control subjects (8.58 
 
±
 
 0.7 n
 
M
 
/ml). The
protein carbonyl content was also significantly (
 
P <
 
 0.05) higher in diabetic
patients with (1.02 
 
±
 
 0.04 nmol/mg protein) and without microangiopathy (0.84 
 
±
 
0.06 nmol/mg protein) compared with control subjects (0.48 
 
±
 
 0.02 nmol/mg
protein). In diabetic subjects, increased p22
 
phox
 
 gene expression was negatively
correlated with HO-1 and positively correlated with TBARS, PCO, HbA
 
1c
 
 and
diabetes duration. In contrast, HO-1 gene expression was correlated negatively
with p22phox, TBARS, PCO, HbA
 
1c
 
 and diabetes duration.
 
Conclusion
 
Our results indicate that increased oxidative damage is seen in
Asian Indians with Type 2 diabetes and microangiopathy and is associated with
increased NADPH oxidase (p22
 
phox
 
) and decreased HO-1 gene expression.
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Introduction
 
There is growing evidence linking the pathogenesis of diabetes
mellitus with oxidative stress [1,2]. Because oxidative stress
results from increased production or decreased removal of
reactive oxygen species (ROS), many studies are now targeted
at identifying the cellular sources of ROS. While there are
multiple sources of ROS, notably xanthine oxidase, uncoupled
nitric oxide synthase, and mitochondria, a major role of NADPH
oxidase as a source of superoxide and hydrogen peroxide has
recently been emphasized [3]. Although NADPH oxidase was
identified and characterized primarily in phagocytic leucocytes
[4], its presence and specific signalling roles have been impli-
cated in many cell types such as fibroblasts, endothelial cells,
vascular smooth muscle cells, adipocytes and pancreatic B-cells
[5–7]. Hence, there is considerable interest in studying whether
NADPH oxidase activity contributes to the pathogenesis or pro-
gression of micro- and macrovascular complications of diabetes.
It is also important to know how the expression of genes
associated with cellular defence against oxidative stress is altered
in patients with Type 2 diabetes. Hemoxygenases (HOs)
catalyse the rate-limiting step in heme degradation, resulting in
the formation of iron, carbon monoxide, and biliverdin, the
latter being subsequently converted to bilirubin by biliverdin
reductase. Recent attention has focused on the biological effects
of product(s) of this enzymatic reaction, which have important
antioxidant, anti-inflammatory, and cytoprotective functions
[8]. Although induction of HO is expected to be an adaptive
and beneficial response to various stimuli, including oxidative
stress, the functional significance of HO gene products is tightly
regulated by the metabolic milieu and, hence, their alterations
need to be studied in diabetes.
Thus, we quantified NADPH oxidase (subunit p22
 
phox
 
) and
hemoxygenase-1 (HO-1) gene expression in patients with Type 2
diabetes with and without microangiopathy, along with markers
of oxidative stress such as lipid peroxidation and protein
carbonyls. As target-specific cellular profiling in humans is
difficult to ascertain 
 
in vivo
 
, we used human leucocytes, a
readily accessible cell model [9,10].
 
Subjects and methods
 
Sample selection
 
Study subjects were recruited from the Chennai Urban Rural
Epidemiology Study (CURES), which is an ongoing epidemiolog-
ical study, conducted on a representative population of Chennai.
The methodology of the study has been published elsewhere
[11,12]. Details such as age, sex and, in diabetic subjects, duration
of diabetes and other details of diabetic therapy were recorded
and clinical examination was carried out in all subjects. All non-
diabetic subjects underwent oral glucose tolerance tests using a
75-g glucose load. Those who were confirmed by oral glucose
tolerance test to have fasting plasma glucose < 6.1 mmol/ l and
a 2-h plasma glucose value < 7.8 mmol/ l were categorized as
normal glucose tolerance. For the present study, we randomly
selected (using computer-generated random numbers) 20 diabetic
subjects with microangiopathy, 19 diabetic subjects without any
microangiopathy and 17 subjects with normal glucose tolerance.
Microangiopathy was diagnosed if nephropathy and/or retino-
pathy were present. Nephropathy was defined as either persistent
proteinuria (
 
≥
 
 500 mg/day) or persistent microalbuminuria
[if albuminuria estimated by albumin creatinine ratio exceeded
30 mg/g of creatinine] in the absence of urinary tract infection
[13,14]. Retinopathy was assessed as described earlier [12,15]
using fundus photography. The pupils were dilated using one
drop each of phenylepherine 10% and tropicamide 1% into both
eyes and the drops were repeated until the best possible mydriasis
was obtained. A trained photographer carried out four-field colour
retinal photography with a Zeiss FF 450 plus camera using
35-mm colour transparencies. The photographs were graded
against standard photographs of the Early Treatment Diabetic
Retinopathy Study grading system for severity of retinopathy.
Hypertension was diagnosed if the subjects had been treated
with anti-hypertensive drugs or had systolic blood pressure
 
≥
 
 140 mmHg or diastolic blood pressure 
 
≥
 
 90 mmHg. Diabetic
subjects without microangiopathy were selected on the basis of
absence of retinopathy (on retinal photography) or nephropathy
(24 h protein excretion < 100 mg/day and urinary albumin
levels < 30 mg/g creatinine). They also had no history of angina
or myocardial infarction and normal 12-lead resting electrocar-
diogram. Informed consent was obtained from all study subjects
and the institutional ethics committee approved the study.
Physical examination included height, weight, and waist and
hip measurements using standardized techniques. Blood pressure
was recorded in the right arm with a mercury sphygmomanometer
(Diamond Deluxe blood pressure apparatus, Pune, India) while
the patients were seated. Two readings were taken 5 min apart and
the mean of the two was taken as the blood pressure. A fasting
blood sample was taken and serum stored at 
 
−
 
70
 
°
 
C until the assays
were performed. Biochemical analyses were carried out on a
Hitachi-912 Autoanalyser (Hitachi, Mannheim, Germany) using
kits supplied by Roche Diagnostics (Mannheim, Germany).
Fasting plasma glucose (GOD-POD (glucose oxidase peroxidase)
method), serum cholesterol (CHOD-PAP (cholesterol oxidase
peroxidase) method), serum triglycerides (GPO-PAP (glycerol
phosphate oxidase peroxidase) method) and high-density lipo-
protein (HDL) cholesterol (direct method–polyethylene glycol-
pretreated enzymes) were measured. Low-density lipoprotein (LDL)
cholesterol was calculated using the Friedewald formula [16].
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Glycated haemoglobin (HbA
 
1c
 
) was estimated by HPLC using the
Variant machine (Bio-Rad Laboratories, Hercules, CA, USA).
 
RNA extraction
 
Total RNA from leucocytes (
 
∼
 
5 
 
×
 
 10
 
6
 
) was extracted using Trizol
reagent (Sigma, St Louis, MO, USA). To check the integrity of the
total RNA, 1 
 
µ
 
g was fractionated on a 1% denaturing agarose
gel. RNA concentration was quantified spectrophotometrically
and had a 280/260 optical density ratio between 1.8 and 2.0.
 
RT-PCR
 
Total RNA (1 
 
µ
 
g) was reverse transcribed in a 25-
 
µ
 
l reaction
containing 5 
 
×
 
 reaction buffer, 0.2 
 
µ
 
g random hexamer primers
(Qiagen, Valencia, CA, USA), 200 units murine leukaemia
virus reverse transcriptase (Amersham Pharamacia Biotech,
Piscataway, NJ, USA), 2.5 mm dNTPs and 50 units ribonuclease
inhibitor in a Thermocycler (Biorad, Hercules, CA, USA)
(55 min at 37
 
°
 
C, 5 min at 95
 
°
 
C) [10].
The p22
 
phox
 
 mRNA expression PCR was probed using specific
primers; their sequence is 5
 
′
 
-GTTTGTGTGCCTGCTGGAGT-
3
 
′
 
 and 5
 
′
 
-TGGGCGGCTGCTTGATGGT-3
 
′
 
 (nucleotide positions
168–187 and 465–485, respectively). The conditions of ampli-
fication were: 95
 
°
 
C for 1 min, 62
 
°
 
C for 1 min and 72
 
°
 
C for
1 min for 30 cycles of amplification. The number of cycles
was determined to assure that the amplification occurs in the
exponential phase. The oligomer primers used for HO-1 gene
expression were 5
 
′
 
-CAGGCAGAGAATGCTGAGTTC-3
 
′
 
 and
5
 
′
 
-GCTTCACATAGCGCTGCA-3
 
′
 
 (nucleotide positions 79–
99 and 332–349, respectively). The conditions of amplification
were: 94
 
°
 
C for 30 s, 58
 
°
 
C for 1 min and 72
 
°
 
C for 1 min for
26 cycles of amplification. PCR products were separated by
2% agarose gel electrophoresis. The housekeeping GAPDH
PCR products obtained by amplifying primers were used as an
internal control.
 
Evaluation of p22
 
phox
 
 and the HO-1 gene product
 
p22
 
phox
 
 and HO-1 gene expression were quantified using Bio-
Rad gel documentation and semiquantitative analysis using its
software. The ratio of p22
 
phox
 
 and HO-1 to GAPDH PCR product,
expressed as peak density, was used as indices of p22
 
phox
 
 and
HO-1 gene expression (in densitometric units).
 
Isolation of lymphocytes
 
Freshly collected peripheral blood was carefully layered on
histopaque gradient and centrifuged at 1600 r.p.m. (500 
 
g
 
) for
30 min. The buffy-coat interface representing lymphocytes was
aspirated and washed three times in phosphate-buffered saline
(PBS) pH 7.4. Protein analysis and ROS measurements were
done in a subset of subjects (
 
n
 
 = 10 in each category).
 
Western blot analysis
 
Protein extracts were obtained from lymphocytes isolated from
5 ml peripheral blood by lysis of cells in RIPA buffer [50 m
 
M
 
Tris pH 8.0, 150 m
 
M
 
 NaCl, 0.1% sodium dodecyl sulfate (SDS),
0.02% sodium azide, 1% NP40, 0.5% sodium deoxycholate].
The cell extract was centrifuged (5 min, 10 000 
 
g
 
) and the super-
natant was stored at 
 
−
 
80
 
°
 
C. Protein concentration of the
samples was determined using Bradford’s assay. Prior to analysis,
50 
 
µ
 
g protein was boiled for 5 min in sample buffer [20 m
 
M
 
Tris-HCl pH 6.8, 1% dithiothreitol, 1% SDS, 20% glycerol,
0.1% bromophenol blue]. The proteins were separated by 12%
SDS–polyacrylamide gel electrophoresis, transferred to nitro-
cellulose membrane, and incubated for 3 h in PBS-0.1% Tween 20
buffer containing 5% bovine serum albumin. The membrane was
then incubated with rabbit anti-p22
 
phox
 
 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) diluted 1 : 200 in blocking
solution for 1 h at room temperature. The membrane was washed
extensively with PBS-0.1% Tween 20 buffer and incubated with
goat anti-rabbit IgG-alkaline phosphatase conjugated antibody
for 1 h at room temperature. The membrane was washed again
and membrane-bound antibodies were visualized by BCIP/NBT
substrate (Bangalore Genei, Bangalore, India). Immunoblotting
with 
 
β
 
-actin was performed as loading control.
 
Quantification of p22
 
phox
 
 protein expression
 
p22
 
phox
 
 protein expression was determined semiquantitatively
using Bio-Rad gel documentation software. The ratio of p22
 
phox
 
to 
 
β
 
-actin western blot products, expressed as peak density, was
used as indices of p22
 
phox
 
 expression (in densitometric units).
 
Measurement of intracellular ROS generation and NADPH 
oxidase activity
 
To measure intracellular ROS production, cells were loaded with
10 
 
µ
 
M
 
 2
 
′
 
,7
 
′
 
-dichlorofluorescein diacetate (H
 
2
 
DCF-DA) for
45 min at room temperature. Cells were centrifuged to remove
the extracellular dye, suspended in HEPES buffer, added to
microplate wells and challenged with 500 
 
µ
 
M
 
 phorbol
myristate acetate (PMA). ROS generation was monitored in
Fluoromax-3 spectrofluorimeter (excitation set at 485 nm and
emission at 530 nm) as a change in the fluorescence intensity
because of the conversion of non-fluorescent dichlorofluorescein
diacetate to the highly fluorescent compound, 2
 
′
 
,7
 
′
 
-dichloroflu-
orescein in the cells [17]. In order to estimate the relative
NADPH oxidase activity, cells treated with PMA were incubat-
ed with different concentrations (0.1, 0.5, 1.0, 5.0, 10.0 
 
µ
 
M
 
) of
diphenylene iodonium (DPI), an inhibitor of NADPH oxidase.
The DPI concentration (IC
 
50
 
) required to inhibit 50% of
NADPH activity was calculated by a curve fitting program
(BioDataFit 1.02; Chang Broscience Inc, Castro Valley, CA, USA).
 
Lipid peroxidation
 
Plasma levels of malonodialdehyde, a marker of lipid peroxidation
was measured as thiobarbituric acid reactive substances (TBARS)
by fluorescence methodology [18,19]. Briefly, plasma (200 
 
µ
 
l)
was treated with 8.1% SDS and 20% acetic acid to solubilize
protein and precipitate it and then heated with thiobarbituric
acid for 1 h at 95
 
°
 
C. The supernatant was then extracted with
butanol : pyridine (15 : 1) to yield a fluorescent product, which
was detected by excitation at 535 nm and emission at 553 nm.
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Absolute malonodialdehyde levels were calculated using the
regression parameters obtained using various concentrations
(0.25–5.0 n
 
M
 
) of the standard, 1,1
 
′
 
,3,3′,-tetramethoxypropane.
Inter- and intra-assay coefficients of variation of the above method
were < 5 and 10%, respectively.
Protein carbonyls
Carbonyl content was quantified by the 2, 4-dinitrophenylhydrazine
(DNPH) assay with slight modifications [20]. To 200 µl plasma,
800 µl of 10 mM DNPH in 2 M HCl was added and allowed to
stand at room temperature for 1 h, vortexing every 10–15 min
to facilitate the reaction with proteins. Plasma protein was
precipitated with 20% trichloroacetic acid (1 : 1 v/v ratio) and
centrifuged at 4°C, 10 000 g for 5 min. Clear supernatant was
discarded and the pellet was washed three times with 1 ml of
ethanol : ethylacetate (1 : 1 v/v ratio). Finally, pellets were
dissolved in 1 ml of 6M-guanidine hydrochloride at 37°C. After
centrifugation at 10 000 g for 5 min to precipitate insoluble
material, the samples were read against complementary blank
on the maximum absorbance showed at 365 nm. Blanks were run
with 2 M HCl alone instead of DNPH reagent. All measurements
were carried out in duplicate. The intra- and interassay coeffi-
cients of variation were 2.2 and 2.8%, respectively. Carbonyl
content was expressed in nmol per mg of protein, using a molar
absorption coefficient of 22 000/M/cm. Protein concentration
was determined using a standard curve with bovine serum
albumin (0.25–5.0 mg/ml) dissolved in guanidine hydrochloride
and read at 280 nm.
Statistical analysis
Comparisons between groups were performed using one-way
ANOVA and a P-value of less than 0.05 was considered statistically
significant. Pearson correlation analysis was carried out between
variables. Risk variables that had significant association with
dependent variable (p22phox and HO-1 gene expression) on
univariate regression, were included as independent variables in
multiple linear regression analysis. Forward regression analysis
was used to investigate relationships between the p22phox and
HO-1 gene expression and age, HbA1c, HDL, HO-1 gene
expression, TBARS and protein carbonyl content (PCO). Care
was taken to avoid intercorrelated variables in the regression
equation. An IC50 calculation was performed using a curvefit
program (BioDataFit 1.02). All analysis was carried out using
Windows-based SPSS statistical package (Version 10.0, SAS
Institute, Chicago, IL, USA).
Results
Table 1 shows the characteristics of the study subjects. None
of the diabetic patients had ketonuria or a history of diabetic
ketosis. Of the 39 Type 2 diabetic subjects, 65% took oral
glucose lowering agents (OHA) and OHA plus insulin was
taken by others (35%). Six of the diabetic subjects without
microangiopathy and 10 with microangiopathy, were on ACE
inhibitors and/or statin or aspirin therapy, in addition to
glucose-lowering agents. Diabetic patients with and without
microangiopathy had significantly higher fasting plasma
glucose, HbA1c, serum cholesterol and triglycerides compared
with control subjects.
Figure 1(a) is a representative illustration of the gene expres-
sion patterns of p22phox, HO-1 and GAPDH in the study groups.
As seen in Fig. 1(b), age-adjusted p22phox gene expression (mean
± SE) was significantly (P < 0.05) higher in diabetic patients with
(0.99 ± 0.04) and without microangiopathy (0.86 ± 0.05)
compared with control subjects (0.66 ± 0.05). Conversely, the
age-adjusted HO-1 gene expression was significantly (P < 0.05)
lower in patients with (0.73 ± 0.03) and without micro-
angiopathy (0.85 ± 0.02) compared with control subjects
(1.06 ± 0.03) (Fig. 1c).
Consistent with the mRNA data, p22phox protein expression
(mean ± SE) in diabetes subjects with (0.77 ± 0.05) and without
(0.67 ± 0.06) microangiopathy was significantly higher when
compared with control (0.44 ± 0.06) subjects (Fig. 2a and b).
PMA-inducible ROS generation in lymphocytes (arbitrary
fluorescence units mean ± SE) was also significantly increased in
diabetic patients without (2221 ± 355) and with complications
Table 1 Clinical characteristics of the study subjects
 
Parameters
Control 
(n = 17)
Type 2 diabetes without 
microangiopathy 
(n = 19)
Type 2 diabetes with
 microangiopathy 
(n = 20)
Age (years) 47 ± 7 53 ± 9* 55 ± 7*
Duration of diabetes (years) 0 5 ± 3 15 ± 5†
Fasting plasma glucose (mmol/ l) 4.7 ± 0.3 7.7 ± 1.6* 9.1 ± 3.1*
Glycated haemoglobin (%) 5.5 ± 0.4 7.4 ± 1.6* 8.9 ± 1.6*
Systolic blood pressure (mmHg) 110 ± 13 134 ± 17* 135 ± 18*
Diastolic blood pressure (mmHg) 70 ± 6 79 ± 8* 78 ± 6*
Serum cholesterol (mmol/ l) 3.9 ± 0.3 5.0 ± 0.8* 5.4 ± 0.8*
Serum triglycerides (mmol/ l) 1.1 ± 0.4 1.8 ± 0.7* 1.9 ± 0.8*
Serum HDL cholesterol (mmol/ l) 1.2 ± 0.2 1.1 ± 0.2* 0.9 ± 0.2*
Serum LDL cholesterol (mmol/ l) 2.5 ± 0.3 3.2 ± 0.9* 3.4 ± 0.9*
Cholesterol : HDL ratio 3.2 ± 0.6 5.0 ± 1.4* 5.0 ± 0.9*
*P < 0.05 compared with control; †P < 0.05 compared with diabetes without microangiopathy.
© 2006 The Authors
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(2325 ± 368) compared with control (880 ± 84) subjects (data
not shown). When DPI, an inhibitor of NADPH oxidase, was
used in a dose-dependent way to determine relative NADPH oxi-
dase activity, the concentration of DPI to achieve 50% reduc-
tion in the PMA-inducible ROS was greater in diabetic patients
with (3.26 µM) and without (2.77 µM) microangiopathy than in
control subjects (1.32 µM) (Fig. 2c). Thus, NADPH oxidase
activity was increased in cells from diabetic patients. p22phox
mRNA levels positively correlated with both protein (r = 0.51;
P = 0.02) and NADPH oxidase activity (r = 0.55; P = 0.01) levels.
The levels of TBARS were significantly (P < 0.05) higher in
patients with (14.36 ± 1.3 nM/ml) and without microangiopathy
(12.20 ± 1.3 nM/ml) compared with control subjects (8.58 ±
0.7 nM/ml) (Fig. 3a). PCO levels were also significantly (P <
0.05) higher in patients with (1.02 ± 0.04 nmol/mg protein)
and without microangiopathy (0.84 ± 0.06 nmol/mg protein)
compared with control subjects (0.48 ± 0.02 nmol/mg
protein) (Fig. 3b).
To determine whether ACE inhibitor/statin therapies
interfere with cellular oxidative stress and/or expression of
NADPH oxidase components, we analysed the data related to
TBARS, PCO, p22phox and HO-1 mRNA levels in diabetic
patients by dividing them into two groups: those taking only
glucose-lowering-agents (group A, n = 23) and those taking
glucose-lowering agents along with ACE inhibitor/statin
(group B, n = 16). No significant differences in estimated
TBARS, PCO, p22phox and HO-1 mRNA levels were observed
(data not shown).
In diabetic subjects, increased p22phox gene expression
correlated negatively with HO-1 (r = –0.31, P = 0.05) and
positively to TBARS (r = 0.58, P = 0.0001), PCO (r = 0.52, P =
0.001), HbA1c (r = 0.34, P = 0.03) and diabetes duration (r =
0.33, P = 0.04). HO-1 gene expression correlated negatively
with p22phox (r = –0.31, P = 0.05), TBARS (r = –0.32, P = 0.04),
PCO (r = –0.32, P = 0.04), HbA1c (r = –0.35, P = 0.03) and
diabetes duration (r = –0.33, P = 0.04). When all study
subjects were analysed together, p22phox gene expression also
correlated negatively with HDL (r = –0.3; P = 0.02). In
contrast, HO-1 gene expression correlated positively with
HDL (r = 0.34; P = 0.01) and negatively with diastolic blood
pressure (r = –0.31; P = 0.02) and systolic blood pressure (r =
–0.36; P = 0.007).
When age, HbA1c, HDL, HO-1 gene expression, TBARS
and PCO were included as potential independent variables in
the forward regression analysis, TBARS and PCO remained in
the final regression equation as predictors of p22phox gene
Figure 1 mRNA expression patterns in the study group. (a) Representative patterns of gene expression of p22phox, hemoxygensase-1 and GAPDH in 
control subjects (lanes 1–4), diabetic subjects without microangiopathy (lanes 6–9) and diabetic subjects with microangiopathy (lanes 11–14). Lanes 5 
and 10 show the DNA ladder (100–500 bp). Densitometric analysis was carried out for p22phox and hemoxygenase-1 gene expression in leucocytes from 
(i) control subjects (n = 17), (ii) diabetic subjects without microangiopathy (n = 19) and (iii) diabetic subjects with microangiopathy (n = 20). Expression 
of both p22phox and HO-1 mRNA were adjusted for the expression of the housekeeping gene GAPDH. (b) Estimated p22phox mRNA expression 
(mean ± SE, indicated by a horizontal line) for 1, 2 and 3 were 0.66 ± 0.05, 0.86 ± 0.05 and 0.99 ± 0.04, respectively. (c) Mean HO-1 mRNA expression 
for 1, 2 and 3 were 1.06 ± 0.03, 0.85 ± 0.02 and 0.73 ± 0.03, respectively. *P < 0.05 compared with control values, †P < 0.05 compared with values 
in diabetic subjects without microangiopathy.
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expression (Table 2). In a similar analysis with HO-1 as the
dependant variable, HbA1c and PCO were significant predictors
of HO-1 gene expression.
Discussion
Asian Indians have high prevalence rates of Type 2 diabetes
and premature coronary heart disease [21]. A number of risk
factors for these diseases may operate via pro-inflammatory
and pro-oxidant mechanisms. Our earlier work indicated hyper-
insulinemia [22], increased insulin resistance [23], increased
pro-thrombogenic factors [24], decreased adiponectin [25],
increased advanced glycation [26] and shortened telomeres [19]
in Asian Indian patients with Type 2 diabetes. It is possible
that these alterations could either induce oxidative damage or
alternatively arise from increased oxidative stress. The present
study is the first to our knowledge to report on the proximal
molecular defects related to oxidative stress and oxidative
damage in relation to diabetes and microangiopathy in Asian
Indians. These observations are significant in that India has the
largest number of people with diabetes in the world [27] and
increased oxidative stress and inflammation could be one of
the molecular mechanisms for predisposition to diabetes and
its complications.
Increased NADPH oxidase activity is implicated in the patho-
genesis of pancreatic B-cell apoptosis [7] and in the development
Figure 2 p22phox protein analysis and NADPH oxidase activity in the study subjects. (a) Representative illustration of protein expression pattern of 
p22phox in control subjects (lanes 2 and 3), diabetic subjects without microangiopathy (lanes 4 and 5) and diabetic subjects with microangiopathy 
(lanes 6 and 7). Lane 1 represents molecular weight marker (15–35 kDa). (b) Cumulative data after densitometric analysis for p22phox protein 
expression in lymphocytes from (1) control subjects (n = 10), (2) diabetic subjects without microangiopathy (n = 10) and (3) diabetic subjects with 
microangiopathy (n = 10). Expression of p22phox was adjusted for the expression of the housekeeping gene β-actin. Estimated p22phox protein expression 
(mean ± SE) for (1), (2) and (3) was 0.44 ± 0.06, 0.67 ± 0.06 and 0.77 ± 0.05, respectively. *P < 0.05 compared with control values. (c) IC50 data for 
NADPH oxidase activity in the study groups. NADPH oxidase activity was inferred from diphenylene iodonium (DPI) inhibition of PMA-induced ROS 
generation in cells as detailed in the Subjects and methods. Estimated IC50 of DPI for control subjects (n = 10), diabetic subjects without 
microangiopathy (n = 10) and diabetic subjects with microangiopathy (n = 10) was 1.32 (), 2.77 () and 3.26 µM (), respectively. *P < 0.05 
compared with control values.
Figure 3 Plasma levels of lipid peroxidation 
(TBARS) and protein carbonyls in the study 
subjects: (1) control subjects (n = 17), (2) 
diabetic subjects without microangiopathy 
(n = 19) and (3) diabetic subjects with 
microangiopathy (n = 20). (a) Mean ± SE 
TBARS in samples (1), (2) and (3) were 
8.58 ± 0.7, 12.2 ± 1.3 and 14.36 ± 1.3, 
respectively. (b) Mean ± SE protein carbonyl 
content for (1), (2) and (3) were 0.48 ± 0.02, 
0.84 ± 0.06 and 1.02 ± 0.04, respectively. 
*P < 0.05 compared with control values, 
†P < 0.05 compared with values in diabetic 
subjects without microangiopathy.
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of diabetic complications, especially diabetic nephropathy
[28]. This stimulated us to look at these parameters in Asian
Indian diabetic subjects with and without microangiopathy, as
they are believed to have a greater predisposition to diabetic
nephropathy [29]. Our findings show that gene expression of
NADPH subunit p22phox is increased in leucocytes of Asian
Indian Type 2 diabetic subjects, and more so in those with micro-
angiopathy. Consistent with the mRNA data, the p22phox pro-
tein expression and NADPH oxidase activity were also
increased in cells from diabetic patients. These data are in
agreement with those of Kim et al. [30] and Avogaro et al.
[10]. In an experimental diabetic nephropathy study, Satoh
et al. [31] have observed NADPH oxidase as a major source of
ROS production in diabetic glomeruli. Similarly, Manea et al.
[32] have also demonstrated that long-term exposure of
pericytes to high glucose results in increased mRNA and
protein expression of the p22phox subunit. Thus, the increased
production of mRNA for p22phox in our study is an important
observation. Moreover, the gene coding for the p22phox is pol-
ymorphic [33] and diabetic subjects with the C242T polymor-
phisms have been reported to be at higher or lower risk of
developing diabetic nephropathy [34,35]. Similarly, the T242T
genotype of the p22phox C242T polymorphism is associated
with decreased risk of severe diabetic retinopathy [36]. Thus,
it would be worthwhile to examine the role of these p22phox
polymorphisms in the genetic susceptibility to diabetic micro-
vascular complications in Asian Indians.
Additionally, it appears that the metabolic milieu in diabetic
patients differentially dictates the formation of the NADPH
oxidase complex and its activation. The relationship between
the metabolic milieu and induction of the oxidative stress is
further substantiated by the finding of positive correlations
between p22phox, HbA1c, lipid peroxidation and protein carbonyl
levels in the diabetic subjects.
Increased HO-1 expression is an adaptive response in
models of oxidative stress-related pulmonary and cardiovascular
disease [37,38] and in monocytes from patients with Type 2
diabetes [10]. However, we observed reduced levels of HO-1
mRNA in patients with Type 2 diabetes, particularly in those
with microangiopathy. HO-1 levels negatively correlated to
p22phox, HbA1c, lipid peroxidation and protein carbonyl levels.
Responses of resistance to oxidative stress may be poor in our
diabetic patients and this might explain the decreased HO-1
gene expression in our study. In contrast, Avogaro et al. [10]
have shown increased HO-1 expression in diabetic subjects.
Interestingly, the negative association of HO-1 and p22phox
expression in our study merits attention because a recent study
[39] demonstrated induction of HO-1 inhibiting NADPH
oxidase activity in macrophages. Our results are also in agree-
ment with a clinical study [40] in which reduced levels of HO-1
mRNA in skeletal muscle from Type 2 diabetic patients were
associated with abnormal insulin-stimulated glucose disposal
and with markers of muscle oxidative capacity. Additionally,
chronic hyperglycaemia lowers HO-1 levels by interfering with
transcription factors in the retina of diabetic rats [41]. Indeed,
repression or induction of the expression of HO-1 is a dynamic
process and depends on the cellular micro-environment [42].
As HO-1 is inducible by many diverse stimuli including NO,
alterations in these stimuli in the diabetic milieu may have a
regulatory role in HO-1 induction. These studies and our
current observations imply a negative association of HO-1 lev-
els with hyperglycaemia and oxidative damage.
The association of reduced levels of HO-1 with increased
blood pressure in our study is of interest because the heme–
hemoxygenase system has been implicated in the regulation of
vascular reactivity and blood pressure [43]. A polymorphism
of the promoter region of the human HO-1 gene is associated
with susceptibility to coronary artery disease in Type 2
diabetic patients [44,45].
While the presence of microangiopathy in diabetic subjects
was strongly related to reduced HO-1 mRNA and increased
protein carbonyl levels, there were no significant differences in
p22phox mRNA and TBARS levels in diabetic subjects with and
without microangiopathy. There may be plausible reasons for
this. Augmentation of NADPH oxidase and lipid peroxidation
may represent an early oxidative stress state [46–48] which
could be reversible, while increased protein carbonyls repre-
sent long-lived cellular changes, connected with duration of
diabetes, and hence might appear as markers of diabetic
microangiopathy. A definite role for reactive carbonyl com-
pounds in the pathogenesis of diabetic nephropathy has been
recently reported [49]. Although oxidative damage markers
might have been improved by associated therapy in diabetic
patients, we did not detect significant changes in p22phox or
HO-1 mRNA expression levels between patients taking only
glucose-lowering agents and those taking glucose-lowering
agents along with other medication. This apparent lack of change
supports the notion that the associated therapy may not
directly alter the sources of pro-oxidant or antioxidant molecular
signals in diabetic subjects. However, more experimental data
on larger numbers of patients are needed to verify this.
Thus, increased p22phox and reduced HO-1 gene expression
seen in our study in patients with diabetes and microangiopathy
may implicate a proximal defect in the regulatory aspect of
oxidative stress. Recent studies indicate that increased oxidative
stress in adipose tissue could be an early step in the metabolic
Table 2 Multivariate regression analysis for the association of p22phox 
and hemoxygenase-1 gene expression in Type 2 diabetic patients
 
Model
Unstandardized coefficients
β se Significance
p22phox
TBARS 0.014 0.005 0.009
PCO 0.241 0.098 0.017
Hemoxygenase-1
HbA1c −0.031 0.010 0.003
PCO −0.192 0.064 0.004
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syndrome [6]. Increased ROS levels and reduced insulin
sensitivity were reported in adipocytes exposed in vitro to
hyperglycaemia [50–52]. Moreover, alterations in ROS
production and/or protective mechanisms have been observed
in diabetic glomeruli and retina [31,41] and genetic variations
in NADPH oxidase were noticed in subjects with diabetic
microangiopathy [34,35]. These studies and our observations,
taken together, suggest that polymorphisms of genes that are
implicated in anti- and pro-oxidative stress, along with
functional studies, may be important in assessing the genetic
susceptibility to diabetes and its complications.
To conclude, the results from this study provide evidence
that genes associated with the production of ROS and antioxi-
dant defence mechanisms are altered in Asian Indian patients
with Type 2 diabetes and the changes are more marked in
those with microangiopathy. These alterations are associated
with markers of oxidative stress, such as lipid peroxidation
and protein carbonyls. It is therefore tempting to speculate that
therapies that can modulate the increase in cellular ROS may
be useful in preventing vascular complications. Suppression
of NADPH oxidase was recently shown to be a promising
therapeutic strategy because localized adventitial delivery of
an NADPH oxidase inhibitor reduced overall vascular O2– and
neointima formation [53]. Given the regulatory aspects and
cross-talk between HO-1 and NADPH oxidase [39], we suggest
that induction of HO-1 by pharmacological means may also
be a novel approach to amelioration of oxidative insults in
various tissues. Hence, attempts to modulate specifically the
sources of ROS production in target tissues by drugs or bioactive
molecules may potentially abrogate the deleterious effects of
hyperglycaemia and serve as novel therapeutic strategies in
diabetic patients.
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